Losartan in Cushing's syndrome

Methods Find Exp Clin Pharmacol. 1998 Mar;20(2):163-8. doi: 10.1358/mf.1998.20.2.472459.

Abstract

Eleven patients with Cushing's syndrome were included in the study. They maintained their usual sodium intake and received a single oral dose of 50 mg of the angiotensin II antagonist receptor losartan for 3 days. Losartan treatment resulted in stimulation of active renin and decrease of plasma and urinary kallikrein activity. Both systolic and diastolic blood pressure decreased independently of baseline level of active renin. The relationship between kallikrein and renin-angiotensin system are discussed.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Oral
  • Antihypertensive Agents / administration & dosage
  • Antihypertensive Agents / therapeutic use*
  • Cushing Syndrome / blood
  • Cushing Syndrome / complications
  • Cushing Syndrome / drug therapy*
  • Humans
  • Hypertension / drug therapy
  • Hypertension / etiology
  • Kallikrein-Kinin System / drug effects
  • Kallikreins / analysis*
  • Losartan / administration & dosage
  • Losartan / therapeutic use*
  • Renin / blood*
  • Renin-Angiotensin System / drug effects

Substances

  • Antihypertensive Agents
  • Kallikreins
  • Renin
  • Losartan